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Merkel cell carcinoma (MCC) was first described in 1972 by Toker, who described five cases of the so-called 
“trabecular carcinoma of the skin”. MCC is a rare, aggressive skin cancer that affects mainly the elderly. Sun ex-
posed areas are mainly affected, specially the head and neck. Immunohistochemical analysis is essential to reach 
a correct diagnosis. According to the origin of MCC, the tumor expresses both epithelial and neuroendocrine 
markers. MCC has a propensity for recurrence, regional and distant metastases. Several treatment options are 
available, such as surgical excision or Moh’s surgery, accompanied by neck dissection or radio and chemotherapy 
in advanced cases. The present study aims to evaluate the clinical behaviour and the evolution of five cases of this 
disease that were treated at our institution (reference to 1100000 inhabitants) in the last five years. It is stressed on 
the bad prognosis of this pathology, which presents high rates of locoregional recurrence, even though the recent 
advances in radio and chemotherapy.
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Friedrich Sigmund Merkel first described in 1875 touch 
cells in the skin of pigs that nowadays are known to 
act as mechanoreceptors. These Merkel cells (MC) are 
also involved in different embryological processes such 
as the formation of subepidermal nerve plexus, eccrine 
sweat glands and hair follicles. MC may derive from 
epidermal cells or from neural crest cells that migrate 
to epidermis during embryogenesis.
Merkel cell carcinoma (MCC) was first described in 
1972 by Toker (1), who described five cases of the so-
called “trabecular carcinoma of the skin”, because of 
the typical architecture of the tumor. MCC is a rare, ag-
gressive skin cancer with an estimated age-adjusted in-
cidence of 0.24 per 100,000 person-years (2) that affects 
mainly the elderly. 
Clinical appearance is often non-specific, occurring 
usually as painless intradermal erythematous lesions, 
with a progressive tendency to ulceration as it grows 
(Fig. 1).
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Pathogenetic factors such as ultraviolet radiation may 
contribute to tumor development. Sun-damaged skins 
are mostly affected, specially the head and neck region 
(3). MCC has been also associated with immunosup-
pression and the development of other synchronous or 
metachronous tumors (4). 
The present study aims to evaluate the clinical behav-
iour and the evolution of five cases of this disease that 
were treated at our institution (reference to 1100000 in-
habitants) in the last five years.
Cases Reports
Case 1 
This case has been published in 2005 (5). A 79-year-old 
woman presented to our department with a 1-month rap-
idly enlarging 3cm tumor on her right cheek. A biopsy of 
the tumor revealed a definite histopathologic diagnosis 
of MCC of intermediate subtype. Immunohistochemi-
cal staining showed positive reactions for antibodies 
against cytokeratin 20, neuronspecific enolase, chrom-
ogranin, γ-enolase, and synaptophysin. Further image 
studies revealed no local, regional, or distant metastatic 
spread of the disease. Patient was classified initially as 
stage II of the Memorial Sloan-Kettering Cancer Center 
staging system.
Twenty days after the biopsy, the tumor decreased to al-
most half its size, and after 49 days it was no longer vis-
ible macroscopically. Three months after the biopsy a 1 
cm residual nodule was removed. The excised specimen 
showed no evidence of tumor cells. After 60 months fol-
low up period, complete clinical and histological regres-
sion of MCC was observed.  
Case 2
A 72-year-old man presented to his private dermatolo-
gist with a red mass located in the subnasal region that 
was diagnosed histopathologically as MCC of interme-
diate subtype. The patient was sent to our department 
and underwent the complete removal of the primary 
lesion and bilateral functional neck dissection (Fig. 1). 
Closure was achieved with local flaps and the treatment 
was complemented with radiotherapy. Nine months af-
ter surgery the patient developed a large left cervical 
metastasis and a left 4 cm parascapular mass. A radi-
cal neck dissection involving the lesion was done and 
the parascapular lesion was also removed with margins. 
Histopathological analysis confirmed the diagnosis of 
distant metastases of MCC. According to stage IV, a 
chemotherapeutic regimen was given (carboplatin and 
etoposide phosphate), which has been maintained until 
now. The patient is free of disease after 54 months since 
the diagnosis.
Case 3
A 52 year-old man presented to our department with 
a 1.5 cm cutaneous lesion affecting the left submental 
region, accompanied with a ipsilateral submental node. 
The diagnosis of MCC with ganglionar dissemination 
was obtained with a biopsy and a fine needle aspiration 
(stage III). Then a complete removal of the lesion and a 
functional ipsilateral neck dissection were performed. 
Treatment was complemented with postoperative ra-
diotherapy. One year after the surgery, the patient died 
because of a pancreatic carcinoma, but without signs of 
locoregional recidive.
Case 4
A 74 year-old man presented to his physician with a 2 
cm mass in the left temporal region. A complete exci-
sion was performed under general anesthesia and the 
diagnosis of MCC was achieved. One month later, both 
left cervical and parotid masses appeared. A fine needle 
aspiration biopsy confirmed the diagnosis of regional 
metastases of the primary tumor (stage III) and so a 
functional neck dissection including the masses and a 
parotidectomy were done. The treatment was comple-
mented postoperatively with radiotherapy. The patient 
is still alive after 36 months after surgery and free of 
disease. 
Case 5
An 81 year-old-woman presented to our Department 
with a red, hard 2 cm mass located in the right check 
(Fig. 2). An incisional biopsy confirmed the diagnosis 
of MCC. Further extension studies confirmed no local, 
regional, or distant metastatic spread of MCC (stage I). 
The treatment consisted in wide excision and ipsilat-
eral supra-omohyoid neck dissection. The closure was 
achieved with the combination of a rhomboidal and a 
Bichat fat flap. The patient is alive and free of disease 
after 24 months of follow-up. 
Fig. 1. Case 2. (a) Patient showed a rapidly growing, non-ulcerated, 
red nodule on subnasal region skin. (b) Complete removal of the le-
sion with adequate margins. (c) Closure of the defect with local flaps. 
(d) CT scan showing local dissemination (left neck)
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Discussion
Merkel cell carcinoma is a very aggressive primary cu-
taneous neoplasm. From a histological point of view, 
MCC is included in a set of tumors known as “small 
round blue cell neoplasms” (6). Pathological analysis 
reveals the presence of small blue cells with sparse 
cytoplasm and medium-sized nuclei, accompanied of 
frequent mitoses and expansion to subcutaneous tissue 
(Fig. 3).
Following histological criteria, MCC can be divided 
into three subtypes. The trabecular subtype presents 
cells arranged in distinctly organoid clusters and 
trabeculae with occasional ribbons. The intermediate 
subtype, the most frequent and aggressive, exhibits a 
solid and diffuse growth pattern with less compacted 
cells. The small cell types shows irregular, hyperchro-
matic cells with scant cytoplasm and malignant cells 
that are arranged in linear patterns infiltrating stromal 
structures. These tumors mimic in form and behavior 
those of small cells of the lung. All cases presented the 
intermediate subtype.
Immunohistochemical analysis is essential to reach 
a correct diagnosis. According to the origin of MCC, 
the tumor expresses both epithelial and neuroendocrine 
markers. Epithelial differentiation is characterized by 
the expression of low-molecular-weight cytokeratins, 
specially Cytokeratin 20 (CK-20) (Fig. 4a). MCC is also 
characteristically negative for Thyroid Transcription 
Factor 1 (TTF-1), which is expressed in epithelial cells 
of the thyroid, lung and brain (Fig. 4b). These markers 
are used simultaneously for the differential diagnosis of 
MCC (7).
Neuroendocrine markers are also expressed by MCC (Fig. 
4c-e), which can include neuron-specific enolase (NSE), 
CD56, Chromogranin A (CrA) and synaptophysin. Ki-67 
index is also characteristically high (Fig. 4f). 
Fig. 2. Case 5. (a) CT scan showing a 2 cm subcutaneous mass in the 
right cheek. (b) Preoperative design of removal and reconstruction. 
(c) Wide extent of the defect with the Bichat flat pad prepared to close 
the intraoral defect. (d) External closure with a rhomboidal flap.
Fig. 3. Case 3. Small blue cells are characterized by sparse cyto-
plasm and medium-sized nuclei, accompanied of frequent mitoses 
(hematoxilin-eosin, x40). 
Fig. 4. Case 4 (a) Punctate or dot-like perinuclear staining with an-
tibody to cytokeratin 20 (40x). (b) Negative staining for  thyroid 
transcription factor allows differential diagnosis with other small 
cells neoplasms (20x). (c) Positive immunostaining for neuron-spe-
cific enolase (x20). (d) Positive immunostaining for chromogranin 
(20x). (e) Positive immunostaining for synaptophysin (20x). (f) Ki-
67 index shows positivity higher than 90%.   
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Memorial Sloan-Kettering Cancer Center group has 
proposed a staging system (8) based on clinical pa-
rameters. This classifies the patients as follows: stage 
I localized disease with a primary tumor dimension <2 
cm, and stage II if primary tumor dimension is >2 cm. 
Patients with regional or distant metastatic disease are 
classified as stages III and IV, respectively.
MCC has a propensity for recurrence, regional and dis-
tant metastases. Several treatment options are available. 
Complete excisions with wide margins or Moh’s sur-
gery have been recommended for treatment of primary 
lesions in order to achieve free margins. In addition, 
prophylactic lymphadenectomy has been also recom-
mended as lymph node metastases develop in approx-
imately 50% of patients (9). Recently, sentinel lymph 
node has been described as a new weapon, providing 
information about prognosis and identifying the drain-
ing lymph node pattern for surgery and adjuvant radia-
tion therapy (RT). 
MCC is also a radiosensitive tumor. In accordance to 
this, patients treated with surgery alone compared with 
those treated with surgery and RT have increased rates 
of locoregional recurrence (10). Several chemothera-
peutic regimens have been used in patients with meta-
static MCC. These include combination therapies with 
cisplatin, doxorubicin and vincristine or with etoposide 
and platinum, with initial overall response rates of ap-
proximately 60% (11). Despite this fact, the median 
overall survival of patients with metastatic disease is 10 
months. All our cases presented initial response to treat-
ment and only one died one year after treatment because 
of a pancreatic carcinoma. So overall survival mean in 
our study was 37.2 months. In we take in account the 
only patient with metastatic disease, the survival after 
beginning with the chemotherapy was 54 months, no-
ticeably higher than the expected.
Although this is a rare phenomenon, there is also the 
possibility of spontaneous regression of MCC (12), as 
we have previously reported. However, the mechanisms 
of this feature remain unclear, apoptotic events have 
been reported to play important roles in its pathogen-
esis.
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